Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2000
10/19/2000CA2370039A1 Apoptosis-associated gene
10/19/2000CA2370033A1 Dna encoding the prostate-specific membrane antigen-like gene and uses thereof
10/19/2000CA2369908A1 Protein/polypeptide-k obtained from momordica charantia and a process for the extraction thereof
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369578A1 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000CA2369472A1 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid)
10/19/2000CA2369454A1 Uses of mammalian ox2 protein and related reagents
10/19/2000CA2369420A1 Treatment of myeloma bone disease with proteasomal and nf-kb activity inhibitors
10/19/2000CA2369413A1 Transmembrane protein expressed in prostate and other cancers
10/19/2000CA2369384A1 Prostate-restricted gene 30p3c8 expressed in prostate cancer
10/19/2000CA2369378A1 Low-molecular inhibitors of complement proteases
10/19/2000CA2369303A1 Method and composition for the treatment of cancer
10/19/2000CA2369267A1 Method for producing amidines
10/19/2000CA2369262A1 Pulmonary administration of dry powder formulations for treating infertility
10/19/2000CA2369156A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1
10/19/2000CA2369096A1 Use of increased-molecular-weight hirudin as an anticoagulant in extracorporeal kidney replacement therapy
10/19/2000CA2368937A1 Prevention of brain damage in stroke
10/19/2000CA2368830A1 Prodrugs of thrombin inhibitors
10/19/2000CA2368648A1 Estrogen receptors and bone
10/19/2000CA2368369A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000CA2366794A1 Channel forming toxins as antiviral agents
10/19/2000CA2366671A1 Methods and reagents for determining enzyme substrate specificity, and uses related thereto
10/19/2000CA2365984A1 Antisense oligonucleotides comprising universal and/or degenerate bases
10/19/2000CA2365945A1 Products and methods for treating ptp lar related diseases
10/19/2000CA2365929A1 Novel method for identifying antibacterial compounds
10/19/2000CA2365918A1 49 human secreted proteins
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365915A1 Recombinant toxin a/toxin b vaccine against clostridium difficile
10/19/2000CA2365914A1 Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
10/19/2000CA2365913A1 Tumor necrosis factor receptor homologs and nucleic acids encoding the same
10/19/2000CA2365912A1 Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2365905A1 48 human secreted proteins
10/19/2000CA2365901A1 Tissue-specific and pathogen-specific toxic agents and ribozymes
10/19/2000CA2365522A1 48 human secreted proteins
10/19/2000CA2365070A1 Combined treatment of multiple sclerosis
10/19/2000CA2364690A1 Novel transduction molecules and methods for using same
10/19/2000CA2364577A1 Regulation of repressor genes using nucleic acid molecules
10/19/2000CA2364572A1 Pcr-based cloning method
10/19/2000CA2364541A1 Genes associated with diseases of the kidney
10/19/2000CA2364536A1 Fragments of virus protein 2 or 3 of polyoma virus, as vehicules for active substances
10/19/2000CA2360318A1 A second mammalian tankyrase
10/19/2000CA2306039A1 Hcv combination therapy
10/19/2000CA2269258A1 Use of crosslinked hemoglobin product in the treatment of vascular disease
10/18/2000EP1045028A1 Deoxyribonucleases
10/18/2000EP1044987A2 Gapped 2'-modified oligonucleotides
10/18/2000EP1044983A1 Antibiotic tkr2999, process for the preparation thereof and microbe
10/18/2000EP1044683A1 One-step dispersion method for the microencapsulation of water soluble substances
10/18/2000EP1044678A1 Lacrimal gland specific emulsions for topical application to ocular tissue
10/18/2000EP1044277A2 Recombinant, active caspases and uses thereof
10/18/2000EP1044274A2 Adenoviral vectors with modified capsid proteins
10/18/2000EP1044273A2 COMPOSITIONS DERIVED FROM $i(MYCOBACTERIUM VACCAE) AND METHODS FOR THEIR USE
10/18/2000EP1044270A2 Apoptosis inducing molecule ii
10/18/2000EP1044269A1 Human vps35/mem3-related protein
10/18/2000EP1044267A2 Novel nucleic acid and polypeptide with homology to the tnf-receptors
10/18/2000EP1044266A2 Human signal peptide-containing proteins
10/18/2000EP1044263A2 CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
10/18/2000EP1044219A1 DNA MOLECULES ENCODING HUMAN NUCLEAR RECEPTOR PROTEIN, nNR5
10/18/2000EP1044218A1 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
10/18/2000EP1044217A2 Sag: sensitive to apoptosis gene
10/18/2000EP1044215A1 Anti-inflammatory phenylalanine derivatives
10/18/2000EP1044212A1 Human fk506 binding proteins
10/18/2000EP1044211A1 36 human secreted proteins
10/18/2000EP1044210A1 Human dendriac and brainiac-3
10/18/2000EP1044206A1 Prodrugs of naaladase inhibitors
10/18/2000EP1044024A1 Use of pigmented retinal epithelial cells for creation of an immune privilege site
10/18/2000EP1044020A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/18/2000EP1044019A1 Methods and compositions for desensitisation
10/18/2000EP1044017A1 Supplement for dialysis patients
10/18/2000EP1044016A1 Stabilised insulin compositions
10/18/2000EP1044015A1 Formulations for amylin agonist peptides
10/18/2000EP1044014A1 Agent for treating allergic or hypersensitivity condition
10/18/2000EP1044013A2 Use of a phosphatidylserine/polypeptide conjugate for inducing autoimmunity in the treatment of cancers
10/18/2000EP1044008A1 Use of aliphatic polyamines for reducing oxalate
10/18/2000EP1044000A1 Combination therapy for the treatment of aids
10/18/2000EP1043987A1 Use of serine protease inhibitors to inhibit pathophysiology and neuropathology in a host
10/18/2000EP1043974A1 Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
10/18/2000EP1043963A1 Osteopontin-based compositions for enhancing bone repair
10/18/2000EP0828507A4 Method for treatment of pain
10/18/2000EP0467932B1 Urokinase-type plasminogen activator receptor
10/18/2000CN1270637A Isolation of a novel senescence-factor gene, P23
10/18/2000CN1270634A Vertebrate telomerase genes and proteins and uses thereof
10/18/2000CN1270632A APPIL-a novel protein with growth effects
10/18/2000CN1270630A Method of treating leukocytes, leukocyte compositions and methods of use thereof
10/18/2000CN1270529A Pharmaceutical compositions containing plasma protein
10/18/2000CN1270527A Use of neurotoxin therapy for treatment of urologic and related disorders
10/18/2000CN1270497A Toxin genes from the bacteria i (xenorhabdus nematophilus) and i (photorhabdus luminescens)
10/18/2000CN1270175A Disinfecting/permeability improved peptide allosteric in protein function region
10/18/2000CN1270061A 弯曲菌疫苗 Campylobacter vaccine
10/18/2000CN1270060A Enteric insulin capsule for treating diabetes
10/18/2000CN1270059A Weight-lossing pill and its prescription
10/18/2000CN1057534C Erythropoietin analogs
10/18/2000CN1057445C Method for preparing anticancer bioactive peptide preparation
10/17/2000US6133463 For use in cosmetic and dermatological compositions for treating or caring for the skin
10/17/2000US6133438 Alkylating unblocked cytidine to form 2'-o-alkylated cytidine, blocking the 5'-hydroxyl moiety, and phosphitylating the 3'-position
10/17/2000US6133437 Antisense nucleic acid which is complementary to specific human and mouse nucleotide sequences and suppresses the biological activity of inhibitor of apoptosis in vitro; anticarcinogenic agents
10/17/2000US6133428 Antibody which binds to an epitope of a specific amino acid sequence
10/17/2000US6133425 Tetramer free, cross linked, polymerized hemoglobin from human blood; has methemoglobin reductase activity from 1.0 to 2.0 units
10/17/2000US6133424 ppRB110 - nuclear phosphoprotein-the retinoblastoma susceptibility gene product
10/17/2000US6133423 Don-1 gene and polypeptides and uses therefor
1 ... 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 ... 3163